Immunotherapy in Lymphoma
Recruiting
Observational Study
Relapsed/refractory High Grade B Cell Lymphoma
High Grade B-cell Lymphoma
Diffuse Large B Cell Lymphoma Relapsed
Primary Mediastinal Large B-Cell Lymphoma
Burkitt Lymphoma
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 19 – 74
- Sex
- Any
- Study type
- Observational
- Participants needed
- 72 (estimated)
- Sponsor
- Sung-Soo Park · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The goal of this observational study is to compare the efficacy of advanced immunochemotherapy and classical immunochemotherapy in relapsed/refractory high grade B cell lymophoma patients. The main question it aims to answer is:
Does advanced immunochemotherapy, including CAR-T therapy, bispecific antibody, and antibody-drug conjugate offer superior survival outcomes than when treated with classi…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Adults aged 19 to 74 years.
* Diagnosed with any of the following after January 2015: diffuse large B cell lymphoma, primary mediastinal large B cell lymphoma, high grade B cell lymphoma, or Burkitt lymphoma
* Patients who have received immunochemotherapy as treatment for rela…
Contacts